INT211133

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.19
First Reported 2007
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 8
Total Number 8
Disease Relevance 3.86
Pain Relevance 4.87

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (MTX1)
MTX1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Adalimumab 497 100.00 Very High Very High Very High
methotrexate 276 100.00 Very High Very High Very High
corticosteroid 8 100.00 Very High Very High Very High
Arthritis 108 96.64 Very High Very High Very High
rheumatoid arthritis 272 96.36 Very High Very High Very High
Leflunomide 5 96.32 Very High Very High Very High
antagonist 75 96.28 Very High Very High Very High
cINOD 11 85.92 High High
Bioavailability 5 85.92 High High
Inflammation 48 84.24 Quite High
Disease Link Frequency Relevance Heat
Seronegative Spondarthritis 88 96.64 Very High Very High Very High
Rheumatoid Arthritis 276 96.36 Very High Very High Very High
Chronic Renal Failure 1 95.32 Very High Very High Very High
Disease 167 90.52 High High
INFLAMMATION 56 85.52 High High
Increased Venous Pressure Under Development 3 84.96 Quite High
Renal Disease 5 81.76 Quite High
Fatigue 7 80.56 Quite High
Chronic Disease 4 79.92 Quite High
Body Weight 2 72.56 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Patients received MTX plus adalimumab 20 mg, 40 mg, or 80 mg or MTX plus placebo every other week (eow) for 24 weeks.
Negative_regulation (received) of MTX associated with adalimumab and methotrexate
1) Confidence 0.19 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1936294 Disease Relevance 0.72 Pain Relevance 0.98
In addition, most patients were able to reduce corticosteroid and/or MTX dose without adversely affecting long-term efficacy (Weinblatt et al 2005).
Negative_regulation (reduce) of MTX associated with corticosteroid and methotrexate
2) Confidence 0.19 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1936294 Disease Relevance 0.52 Pain Relevance 0.73
Patients received MTX plus adalimumab 20 mg, 40 mg, or 80 mg or MTX plus placebo every other week (eow) for 24 weeks.
Negative_regulation (received) of MTX associated with adalimumab and methotrexate
3) Confidence 0.19 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1936294 Disease Relevance 0.78 Pain Relevance 0.99
Other folate enzymes are not directly inhibited by MTX, such as methylenetetrahydrofolate reductase (MTHFR), but their expression level may contribute to the antifolate effects of MTX [57].
Negative_regulation (effects) of MTX associated with methotrexate
4) Confidence 0.19 Published 2008 Journal Current Genomics Section Body Doc Link PMC2691664 Disease Relevance 0.38 Pain Relevance 0.92
14 days after cholestyramine or activated charcoal washout), but continued to receive concomitant MTX (10?
Negative_regulation (receive) of MTX associated with methotrexate
5) Confidence 0.09 Published 2010 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC2938895 Disease Relevance 0.30 Pain Relevance 0.34
MTX was found to reduce the apparent clearance of adalimumab after single and multiple dosing by 29% and 44% respectively.
Negative_regulation (reduce) of MTX associated with adalimumab and methotrexate
6) Confidence 0.08 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721299 Disease Relevance 0.38 Pain Relevance 0.60
MTX is a folic acid analog that inactivates the enzyme dihydrofolate reductase and thus the production of thymidylate, which is essential for DNA replication.
Negative_regulation (inactivates) of MTX associated with methotrexate
7) Confidence 0.04 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2893757 Disease Relevance 0.79 Pain Relevance 0.26
GsMTx-4 has been reported to be a specific stretch-activated channel inhibitor [31], [32], while L-methionine and fluphenazine show reasonable selectivity as TREK channel antagonists [17], [33], [34].


Negative_regulation (inhibitor) of GsMTx-4 associated with antagonist
8) Confidence 0.01 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2928262 Disease Relevance 0 Pain Relevance 0.05

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox